Related Experiment Video
Updated: May 11, 2026
Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine
Published on: October 13, 2023
Interleukin-12 prevents colorectal cancer liver metastases in mice
Fei Shen1, Jiang-Lin Li, Weng-Song Cai
1Department of General Surgery, Guangzhou First People's Hospital, Guangzhou Medical College, Guangzhou, People's Republic of China.
Abstract:
Interleukin (IL)-12 has emerged to be a prospective molecule for antitumor therapies with many types of cancers. Here we examine the effect of IL-12 treatment in preventing the colorectal cancer liver metastasis in a mice model. At different doses, we found that IL-12 treatment decreased the formation of liver metastasis sites and the percentage of metastasis volume in the liver. Additionally, this treatment leads to improved survival function of mice after tumor cell transplantation. We believe that IL-12 based therapy provided a novel treatment to colorectal cancer patients suffering from liver metastasis.
Insights
Interleukin-12 (IL-12) therapy effectively reduced colorectal cancer liver metastasis in mice. This treatment also improved survival, offering a promising new strategy for patients with liver metastasis.
Area of Science:
- Oncology
- Immunotherapy
- Cancer Metastasis
Background:
- Colorectal cancer frequently metastasizes to the liver, significantly impacting patient prognosis.
- Interleukin-12 (IL-12) is recognized for its potential in antitumor therapies.
- Effective treatments for colorectal cancer liver metastasis remain a critical clinical need.
Purpose of the Study:
- To investigate the efficacy of Interleukin-12 (IL-12) in preventing colorectal cancer liver metastasis.
- To evaluate the impact of IL-12 treatment on metastasis volume and survival rates in a preclinical model.
Main Methods:
- A mouse model of colorectal cancer liver metastasis was utilized.
- Mice received varying doses of IL-12 treatment.
- Tumor burden, metastasis formation, and survival were assessed.
Main Results:
- IL-12 treatment significantly decreased the number of liver metastasis sites.
- A reduction in the percentage of liver occupied by metastasis was observed.
- Improved survival function was noted in mice treated with IL-12.
Conclusions:
- IL-12 demonstrates significant potential in inhibiting colorectal cancer liver metastasis.
- IL-12 based therapy represents a novel and promising treatment approach for colorectal cancer patients with liver metastasis.
- Further clinical investigation of IL-12 for this indication is warranted.
